de BlackRock BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 239 M | Comprar |
23,893,036
+1,242,048
| +5% | +USD 11.2 M | ﹤0.01% | 1686 |
|
|
2026
Q1 | USD 216 M | Comprar |
22,650,988
+1,513,197
| +7% | +USD 11.8 M | ﹤0.01% | 1627 |
|
|
2025
Q4 | USD 165 M | Vender |
21,137,791
-108,085
| -0.5% | -USD 781 k | ﹤0.01% | 1805 |
|
|
2025
Q3 | USD 161 M | Vender |
21,245,876
-179,973
| -0.8% | -USD 1.5 M | ﹤0.01% | 1801 |
|
|
2025
Q2 | USD 192 M | Vender |
21,425,849
-1,343,397
| -6% | -USD 12.5 M | ﹤0.01% | 1639 |
|
|
2025
Q1 | USD 171 M | Comprar |
22,769,246
+674,083
| +3% | +USD 5.44 M | ﹤0.01% | 1686 |
|
|
2024
Q4 | USD 166 M | Comprar |
22,095,163
+1,179,192
| +6% | +USD 8.95 M | ﹤0.01% | 1770 |
|
|
2024
Q3 | USD 159 M | Comprar |
20,915,971
+959,716
| +5% | +USD 7.3 M | ﹤0.01% | 1794 |
|
|
2024
Q2 | USD 123 M | Comprar |
19,956,255
+1,515,526
| +8% | +USD 8.36 M | ﹤0.01% | 1905 |
|
|
2024
Q1 | USD 93.7 M | Vender |
18,440,729
-240,641
| -1% | -USD 1.35 M | ﹤0.01% | 2093 |
|
|
2023
Q4 | USD 112 M | Comprar |
18,681,370
+1,907,066
| +11% | +USD 11.1 M | ﹤0.01% | 2005 |
|
|
2023
Q3 | USD 119 M | Comprar |
16,774,304
+1,278,601
| +8% | +USD 9.19 M | ﹤0.01% | 1892 |
|
|
2023
Q2 | USD 109 M | Comprar |
15,495,703
+670,905
| +5% | +USD 5.38 M | ﹤0.01% | 1989 |
|
|
2023
Q1 | USD 124 M | Vender |
14,824,798
-94,157
| -0.6% | -USD 906 k | ﹤0.01% | 1873 |
|
|
2022
Q4 | USD 171 M | Comprar |
14,918,955
+1,143,960
| +8% | +USD 14.3 M | 0.01% | 1649 |
|
|
2022
Q3 | USD 174 M | Vender |
13,774,995
-212,423
| -2% | -USD 2.73 M | 0.01% | 1580 |
|
|
2022
Q2 | USD 148 M | Vender |
13,987,418
-114,557
| -0.8% | -USD 1.18 M | ﹤0.01% | 1754 |
|
|
2022
Q1 | USD 229 M | Vender |
14,101,975
-685,420
| -5% | -USD 11 M | 0.01% | 1577 |
|
|
2021
Q4 | USD 205 M | Vender |
14,787,395
-543,463
| -4% | -USD 7.19 M | 0.01% | 1720 |
|
|
2021
Q3 | USD 220 M | Vender |
15,330,858
-150,469
| -1% | -USD 2.37 M | 0.01% | 1639 |
|
|
2021
Q2 | USD 245 M | Vender |
15,481,327
-760,448
| -5% | -USD 10.3 M | 0.01% | 1621 |
|
|
2021
Q1 | USD 165 M | Vender |
16,241,775
-17,970
| -0.1% | -USD 185 k | ﹤0.01% | 1852 |
|
|
2020
Q4 | USD 121 M | Comprar |
16,259,745
+315,852
| +2% | +USD 1.63 M | ﹤0.01% | 1961 |
|
|
2020
Q3 | USD 54.8 M | Comprar |
15,943,893
+1,276,979
| +9% | +USD 5.47 M | ﹤0.01% | 2238 |
|
|
2020
Q2 | USD 69.9 M | Comprar |
14,666,914
+1,271,297
| +9% | +USD 5.08 M | ﹤0.01% | 2068 |
|
|
2020
Q1 | USD 26.8 M | Comprar |
13,395,617
+1,245,406
| +10% | +USD 3.43 M | ﹤0.01% | 2447 |
|
|
2019
Q4 | USD 41.9 M | Comprar |
12,150,211
+2,555,431
| +27% | +USD 6.43 M | ﹤0.01% | 2475 |
|
|
2019
Q3 | USD 27.5 M | Comprar |
9,594,780
+668,889
| +7% | +USD 2.08 M | ﹤0.01% | 2633 |
|
|
2019
Q2 | USD 33.8 M | Comprar |
8,925,891
+228,525
| +3% | +USD 1.38 M | ﹤0.01% | 2551 |
|
|
2019
Q1 | USD 70.8 M | Vender |
8,697,366
-152,061
| -2% | -USD 1.3 M | ﹤0.01% | 2085 |
|
|
2018
Q4 | USD 71.4 M | Comprar |
8,849,427
+79,571
| +0.9% | +USD 619 k | ﹤0.01% | 2023 |
|
|
2018
Q3 | USD 66.9 M | Comprar |
8,769,856
+1,013,905
| +13% | +USD 6.81 M | ﹤0.01% | 2220 |
|
|
2018
Q2 | USD 44.4 M | Comprar |
7,755,951
+281,532
| +4% | +USD 1.55 M | ﹤0.01% | 2431 |
|
|
2018
Q1 | USD 35.7 M | Vender |
7,474,419
-139,861
| -2% | -USD 719 k | ﹤0.01% | 2462 |
|
|
2017
Q4 | USD 37.4 M | Comprar |
7,614,280
+993,100
| +15% | +USD 4.81 M | ﹤0.01% | 2450 |
|
|
2017
Q3 | USD 34.7 M | Comprar |
6,621,180
+362,803
| +6% | +USD 1.86 M | ﹤0.01% | 2495 |
|
|
2017
Q2 | USD 34.8 M | Comprar |
6,258,377
+244,100
| +4% | +USD 1.49 M | ﹤0.01% | 2463 |
|
|
2017
Q1 | USD 50.5 M | Comprar |
6,014,277
+6,004,070
| +58,823% | +USD 41.8 M | ﹤0.01% | 2213 |
|
|
2016
Q4 | USD 65 k | Comprar |
10,207
+231
| +2% | +USD 1.2 k | ﹤0.01% | 2800 |
|
|
2016
Q3 | USD 44 k | Vender |
9,976
-6,699
| -40% | -USD 26.8 k | ﹤0.01% | 3022 |
|
|
2016
Q2 | USD 48 k | Comprar |
16,675
+11,883
| +248% | +USD 36.9 k | ﹤0.01% | 2948 |
|
|
2016
Q1 | USD 14 k | Comprar |
4,792
+2,769
| +137% | +USD 12.3 k | ﹤0.01% | 3006 |
|
|
2015
Q4 | USD 21 k | Comprar |
2,023
+551
| +37% | +USD 5.48 k | ﹤0.01% | 2537 |
|
|
2015
Q3 | USD 17 k | Vender |
1,472
-58,800
| -98% | -USD 785 k | ﹤0.01% | 2472 |
|
|
2015
Q2 | USD 900 k | Vender |
60,272
-3,345
| -5% | -USD 38 k | ﹤0.01% | 1402 |
|
|
2015
Q1 | USD 575 k | Mantener |
63,617
| – | – | ﹤0.01% | 1500 |
|
|
2014
Q4 | USD 774 k | Mantener |
63,617
| – | – | ﹤0.01% | 1252 |
|
|
2014
Q3 | USD 622 k | Vender |
63,617
-4,300
| -6% | -USD 52.7 k | ﹤0.01% | 1309 |
|
|
2014
Q2 | USD 866 k | Comprar |
67,917
+67,903
| +485,021% | +USD 661 k | ﹤0.01% | 1232 |
|
|
2014
Q1 | USD 0 | Comprar |
+14
| Nuevas | +USD 149 | ﹤0.01% | 3125 |
|
Otros fondos que tienen BCRX en su cartera
Posición de BlackRock en BCRX: resumen de T2 2026
BlackRock aumentó su participación en BioCryst Pharmaceuticals (BCRX) en 5.5% durante T2 2026, al comprar aproximadamente USD 11.2 M y elevar la posición a 23,893,036 acciones con un valor de USD 239 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1686.
BlackRock reportó por primera vez una posición en BCRX en T1 2014 y la ha mantenido durante 50 trimestres desde entonces. La posición alcanzó su máximo de USD 245 M en T2 2021. Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T2 2026, BlackRock tenía 23,893,036 acciones de BioCryst Pharmaceuticals con un valor de USD 239 M.
- BlackRock compró 1,242,048 acciones de BioCryst Pharmaceuticals en T2 2026, por un monto estimado de USD 11.2 M.
- BioCryst Pharmaceuticals representó ﹤0.01% de la cartera de BlackRock en T2 2026 y fue su posición número 1686.
- BlackRock reportó por primera vez una posición en BioCryst Pharmaceuticals en T1 2014 y la ha mantenido durante 50 trimestres desde entonces.
- La posición de BlackRock en BioCryst Pharmaceuticals alcanzó su máximo de USD 245 M en T2 2021.
- Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en cartera.
Según el Informe 13F de BlackRock correspondiente a T2 2026, presentado el 7 ago 2026.